<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04581512</url>
  </required_header>
  <id_info>
    <org_study_id>EP0042-101</org_study_id>
    <nct_id>NCT04581512</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and Tolerability of EP0042</brief_title>
  <official_title>A Modular, Multipart, Multi-arm, Open-label, Phase I/IIa Study to Evaluate the Safety and Tolerability of EP0042 Alone and in Combination With Anti-cancer Treatments in Patients With Advanced Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ellipses Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ellipses Pharma</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A research study looking at a new treatment for patients with advanced cancer, to investigate&#xD;
      different doses of the experimental study drug, EP0042, in order to determine a dose, which&#xD;
      is safe, well-tolerated and likely to be effective in treating AML (acute myeloid leukaemia).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 2, 2020</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of dose-limiting toxicities (DLTs) from the first dose through the end of the DLT observation period.</measure>
    <time_frame>First cycle of treatment (28 Days)</time_frame>
    <description>Incidence of dose-limiting toxicities (DLT)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">63</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Chronic Myelomonocytic Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>EP0042</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EP0042</intervention_name>
    <description>EP0042 Oral 20 mg 50 mg capsules</description>
    <arm_group_label>EP0042</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        General:&#xD;
&#xD;
          1. Male or female patients aged ≥ 18 years of age, at the time of informed consent, with&#xD;
             histological or cytological confirmation of an advanced malignancy&#xD;
&#xD;
          2. Ability to understand and provide written informed consent before any study-specific&#xD;
             procedures, sampling, or analyses, including access to archival tumour tissue&#xD;
&#xD;
          3. Ability to swallow and retain oral medication&#xD;
&#xD;
          4. Sufficient life expectancy to allow the patient to complete at least 1 cycle (28 days)&#xD;
             of the treatment period.&#xD;
&#xD;
          5. ECOG Performance Status of 0, 1 or 2 at Screening&#xD;
&#xD;
          6. In the opinion of the investigator, all other relevant medical conditions must be&#xD;
             well-managed and stable for at least 28 days prior to first administration of study&#xD;
             drug&#xD;
&#xD;
             Part A (escalation phase) only:&#xD;
&#xD;
          7. Patients with pathologically confirmed/documented AML or MDS, as defined by the 2017&#xD;
             European LeukaemiaNet (ELN) recommendations, or CMML, as defined by World Health&#xD;
             Organization (WHO) criteria, who have relapsed from or are refractory to previous&#xD;
             therapy&#xD;
&#xD;
             Part B (Expansion cohort patients) only:&#xD;
&#xD;
          8. Patients with pathologically confirmed/documented AML, as defined by the 2017 European&#xD;
             LeukaemiaNet (ELN) recommendations, who either decline or are unsuitable for standard&#xD;
             therapy, or who are refractory to, or have relapsed after, initial treatment, with no&#xD;
             more than 3 prior lines of therapy. A prior line of therapy is defined as:&#xD;
&#xD;
               -  Treatment to induce remission with anthracycline/cytarabine (eg '3+7'&#xD;
                  daunorubicin 60 mg/m2 [3 days/cycle] plus cytarabine 100-200 mg/m2 [7&#xD;
                  days/cycle], +/-midostaurin&#xD;
&#xD;
                    -  mylotarg and including CPX-351, FLAG-ida or similar intensive regimens).&#xD;
&#xD;
               -  Low dose cytarabine or hypomethylating agents (azacitidine or decitabine)&#xD;
&#xD;
               -  Treatment with single agent FLT3 inhibitors (quizartinib, gilteritinib,&#xD;
                  crenolanib) for relapsed disease&#xD;
&#xD;
               -  Transplantation (allogeneic) in active disease.&#xD;
&#xD;
             The following is not considered a prior line of therapy:&#xD;
&#xD;
               -  Consolidation cycles including those with midostaurin or mylotarg or quizartinib&#xD;
&#xD;
               -  Transplantation (allogeneic) given during remission. Other prior treatments may&#xD;
                  be discussed with the Medical Monitor for consideration.&#xD;
&#xD;
             Approximately 20 evaluable patients will be included with FLT-3 ITD AML and&#xD;
             approximately 10 evaluable patients with FLT-3 wild type AML, both confirmed by local&#xD;
             laboratories within 28 days prior to dosing&#xD;
&#xD;
             Contraception:&#xD;
&#xD;
          9. Female patients should either be of non-child-bearing potential or must agree to use&#xD;
             highly effective methods of contraception from Screening until 6 months following&#xD;
             administration of the last dose of study drug&#xD;
&#xD;
         10. Male patients must use double barrier contraception from enrolment through treatment&#xD;
             and for 6 months following administration of the last dose of study drug&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients with any of the following will not be included in the study:&#xD;
&#xD;
        Disease Under Study and Prior Anticancer Treatment:&#xD;
&#xD;
          1. Suspected brain and/or leptomeningeal metastases that are symptomatic or untreated or&#xD;
             that require current therapy&#xD;
&#xD;
          2. Acute promyelocytic leukaemia (FAB:M3)&#xD;
&#xD;
          3. Systemic anti-cancer therapy for the disease under study within 4 weeks of the first&#xD;
             dose of study treatment. (Concomitant hydroxyurea is acceptable and will be permitted&#xD;
             throughout the screening period and during first 2 cycles of study treatment)&#xD;
&#xD;
          4. Ongoing toxic manifestations of previous treatments that have not reduced to at least&#xD;
             CTCAE Grade 1. Exceptions to this are alopecia or certain Grade 2 treatment related&#xD;
             toxicities, which in the opinion of the Investigator should not exclude the patient.&#xD;
&#xD;
          5. Transplantation (allogeneic or autologous) within last 90 days, or on active&#xD;
             immunosuppressive therapy for graft versus host disease in last 2 weeks Laboratory&#xD;
             Parameters&#xD;
&#xD;
          6. Patient with any out-of-range laboratory values defined as shown below. Haematology&#xD;
             evaluations must be performed ≥7 days from any blood or blood product transfusion and&#xD;
             ≥14 days from any dose of hematologic growth factor.&#xD;
&#xD;
               -  Serum creatinine &gt; 1.5 x upper limit of normal (ULN) and/or creatinine clearance&#xD;
                  (calculated using Cockcroft-Gault formula, or measured) &lt; 50 mL/min&#xD;
&#xD;
          7. Inadequate liver function as demonstrated by&#xD;
&#xD;
               -  serum bilirubin ≥3 times the upper limits of normal range (ULN) or&#xD;
&#xD;
               -  alanine aminotransferase (ALT) ≥3 times the ULN or&#xD;
&#xD;
               -  aspartate aminotransferase (AST) ≥3 times the ULN or&#xD;
&#xD;
               -  AST or ALT ≥5 times the ULN in the presence of liver involvement by leukaemia&#xD;
&#xD;
             Medical History and Concomitant Medications:&#xD;
&#xD;
          8. Confirmed QTcF &gt; 470 msec on screening ECG or congenital long QT syndrome&#xD;
&#xD;
          9. Receiving an investigational anti-cancer treatment concurrently or within 14 days or&#xD;
             five half-lives of either the parent drug or any active metabolite prior to the start&#xD;
             of treatment with EP0042. Patients may receive hydroxyurea throughout the screening&#xD;
             period and during the first 2 cycles of study treatment.&#xD;
&#xD;
         10. Any evidence of severe or uncontrolled systemic or current unstable or uncompensated&#xD;
             respiratory or cardiac conditions which makes it undesirable for the patient to&#xD;
             participate in the study or which could jeopardize patient safety&#xD;
&#xD;
         11. Current refractory nausea and vomiting, malabsorption syndrome, disease significantly&#xD;
             affecting gastrointestinal (GI) function, re-section of the stomach, extensive small&#xD;
             bowel re-section that is likely to affect absorption, symptomatic inflammatory bowel&#xD;
             disease, partial or complete bowel obstruction, or gastric restrictions and bariatric&#xD;
             surgery such as gastric bypass.&#xD;
&#xD;
         12. Known history of human immunodeficiency virus infection (HIV) (testing is not&#xD;
             required), active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.&#xD;
             Testing for HBV or HCV status is not necessary unless clinically indicated or the&#xD;
             patient has a history of HBV or HCV infection&#xD;
&#xD;
         13. Hypersensitivity to EP0042 or D -α-Tocopherol polyethylene glycol succinate (TPGS)&#xD;
&#xD;
         14. Malignant disease other than that being treated in this study, with the following&#xD;
             exceptions:&#xD;
&#xD;
               -  Malignancies that were treated curatively and have not recurred within 2 years&#xD;
                  prior to study treatment&#xD;
&#xD;
               -  Completely resected basal cell and squamous cell skin cancers&#xD;
&#xD;
               -  Any malignancy considered to be indolent and that has never required therapy&#xD;
&#xD;
               -  Completely resected carcinoma in situ of any type&#xD;
&#xD;
         15. Any medical condition that would, in the investigator's judgment, prevent the&#xD;
             patient's participation in the clinical study due to safety concerns, compliance with&#xD;
             clinical study procedures, or interpretation of study results&#xD;
&#xD;
         16. Any major surgical procedure (in the investigator's judgement) within 2 weeks of the&#xD;
             first dose of study drug (minimally invasive procedures such as bronchoscopy, tumour&#xD;
             biopsy, insertion of a central venous access device, and insertion of a feeding tube&#xD;
             are not considered major surgery and are not exclusionary)&#xD;
&#xD;
         17. Patients with a history of, or currently suffering from, severe psychiatric diseases&#xD;
             such as mania, manic depression or psychoses&#xD;
&#xD;
         18. Pregnant, likely to become pregnant, or lactating women (where pregnancy is defined as&#xD;
             the state of a female after conception and until the termination of gestation)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Taussig</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Royal Marsden, UK</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Helen Bridger</last_name>
    <phone>+44 (0) 2037430992</phone>
    <email>helen@ellipses.life</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>James Sandy</last_name>
    <phone>+44 (0) 2037430992</phone>
    <email>James@ellipses.life</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Royal Perth Hospital</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kanako Ohara</last_name>
      <email>Kanako.Ohara@health.wa.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Amsterdam UMC</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081HV Amsterdam</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeroen Janssen, Dr</last_name>
      <email>hematology@amsterdamumc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <zip>3000 CA Rotterdam</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mojca Jongen-Lavrencic, Dr</last_name>
      <email>TMhema.ctc@erasmusmc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden</name>
      <address>
        <city>London</city>
        <state>UK</state>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Taussig, Dr</last_name>
    </contact>
    <contact_backup>
      <email>janet.blackmore@rmh.nhs.uk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University College London Hospital</name>
      <address>
        <city>London</city>
        <zip>W1T 7HA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenny O'Nions, Dr</last_name>
      <email>uclh.referrals.clinicalresearchfacility@nhs.net</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 16, 2020</study_first_submitted>
  <study_first_submitted_qc>October 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2020</study_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Chronic</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Juvenile</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

